Get the Stockscreener App
25.42
1.68%
-0.7499
Gh Research Plc stock is traded at $25.42, with a volume of 11,253.
It is down -1.68% in the last 24 hours and up +20.07% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$26.17
Open:
$26.18
24h Volume:
11,253
Relative Volume:
0.05
Market Cap:
$1.75B
Revenue:
-
Net Income/Loss:
$-48.26M
P/E Ratio:
-32.18
EPS:
-0.7899
Net Cash Flow:
$-45.04M
1W Performance:
-4.28%
1M Performance:
+20.07%
6M Performance:
+43.34%
1Y Performance:
+71.48%
1-Day Range:
$25.47
$26.43
1-Week Range:
$25.53
$27.30
52-Week Range:
$11.32
$28.96
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
25.47 | 1.84B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
519.06 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.00 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
927.59 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.58 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.90 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
GH Research Plc Actuals & Estimates (FWB:1KA) - TradingView
Pre-Market Movement | GH Research Shares Surge to 52-Week High - 富途牛牛
GHRS Forecast — Price Target — Prediction for 2027 - TradingView
GHRS Stock Price and Chart — NASDAQ:GHRS - TradingView
(GHRS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
GH Research PLC stock hits 52-week high at 25.98 USD - Investing.com
GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM - TipRanks
GH Research PLC (GHRS) re-elects directors and ratifies PwC Ireland at AGM - Stock Titan
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year - Sahm
GH Research Plc Actuals & Estimates (MUN:1KA) - TradingView
These analysts revise their forecasts on GH Research after Q1 results - MSN
GH Research PLC (GHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GH RESEARCH PLC (GHRS) Stock Chart - ChartMill
GH Research PLC (GHRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
What GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders - simplywall.st
GH Research PLC (GHRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
GH Research PLC (GHRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GH Research PLC (GHRS) Institutional Confidence - TradingKey
GH Research PLC (GHRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GH Research PLC (GHRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GH Research PLC (GHRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GH Research PLC (GHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
(GHRS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
GH Research (GHRS) Stock Valuation After Positive Phase 2a Mebufotenin Data In Postpartum Depression - Sahm
GH Research (GHRS) Bounces 2.23% as Shares Test Key Resistance at $22.18Exhaustion Gap - newsline.com
GHRS Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss, Stock Rises on Pipeline Progress - dars.gov.et
GHRS Q1 2026 Earnings: Clinical-Stage Biotech Reports Narrower-Than-Expected Operating Loss Amid Pipeline ProgressEarnings Power Value - newsline.com
Do GH Research’s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy? - simplywall.st
GH Research PLC (GHRS) Gains Ground After Testing Support, Resistance in FocusAscending Triangle - newsline.com
GH Research Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Clinical DevelopmentReturn On Assets - newsline.com
GHRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
H.C. Wainwright Maintains Buy Rating on GH Research (GHRS) - Insider Monkey
GH Research earnings ahead: Can cash sustain Phase 3 ambitions? - Investing.com
5 Stocks That Have the Potential to Rise 1000% - Insider Monkey
(GHRS) Risk Channels and Responsive Allocation - Stock Traders Daily
GH Research Publishes Positive Phase 2a Postpartum Depression Data and Secures CINP 2026 Slots for GH001 - TipRanks
GH Research (NASDAQ: GHRS) highlights Phase 2 GH001 results in postpartum and treatment-resistant depression - Stock Titan
GH Research publishes phase 2a postpartum depression results By Investing.com - Investing.com Australia
GH Research publishes phase 2a postpartum depression results - Investing.com
GH Research Announces Publication of Phase 2a Postpartum Depression Results - Yahoo Finance UK
GHRS Q1 2026 Earnings: Miss on EPS as Clinical-Stage Biotech Deepens R&D InvestmentFinancial Health Score - newsline.com
Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use - AOL.com
GH Research (GHRS) Surges Over 7%: Testing Key Resistance at $25.19Chandelier Stop - newsline.com
GH Research (GHRS) Surges 7.19% as Breakout Above $25.19 Resistance Becomes Key TestOvernight Profile - The Legal Advocate
Certain Options of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
62,029,395 Common Stock of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
GHRS Q1 2026 Earnings: Wider-than-Expected Loss Underscores Clinical-Stage ChallengesEarnings Miss Streak - newsline.com
GHRSGH Research PLC Stock Price and Quote - Finviz
GH Research (GHRS) Jumps 3.35% as Shares Approach Key Resistance at $24.0Insider Selling Alerts - The Legal Advocate
(GHRS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
GH Research Stock Moves as Market Eyes Data in Holiday Week - Bez Kabli
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.95%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):